1 / 23

How to manage G1 relapsers and non-responders

How to manage G1 relapsers and non-responders. George V. Papatheodoridis, MD Associate Professor in Medicine & Gastroenterology 2nd Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital, Athens, Greece. Case 1 - AM. 01/2008

jemima
Download Presentation

How to manage G1 relapsers and non-responders

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. How to manage G1 relapsers and non-responders George V. Papatheodoridis, MD Associate Professor in Medicine & Gastroenterology 2nd Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital, Athens, Greece

  2. Case 1 - AM 01/2008 • Male, 42 y.o., H: 1.75 m, W 77 Kg, BMI 25.1 Kg/m2, no other disease G1a, HCV RNA 1,200,000 IU/mL, Fibroscan 6.3 (0.9) kPa • Peg-IFNa-2a (180 μg/wk) + RBV (1.2 g/d) x48 wks • HCV RNA (-) at 12 & 48 wks, (+) at 72 wks 2009-2011 • No therapy - Transient, mild ALT elevations 12/2011 • HCV RNA 2,200,000 IU/mL, Fibroscan 6.0 (1.0) kPa

  3. Case 1 – AM – Question 1 Would you retreat this patient today? (BOC/TPV available) No Yes a. Peg-IFN + RBV b. Peg-IFN + RBV + BOC/TPV

  4. RESPOND-2: SVR after ΒΟC based therapyin G1 relapsers 4-wk PR + 32-wk BOC+PR ± 12-wk PR 4-wk PR + 44-wk BOC+PR 48-wk PR SVR (%) FO/F1/F2/F3 Relapsers F4 All relapsers N= 42 87 81 6 14 14 Ν= 51 105 103 Bacon BR et al. ΝΕJM 2011; 364: 1207-17

  5. PROVE 3 / REALIZE: SVR under TPV based therapy in G1 relapsers 100 P< .0001 P< .0001 88 83 80 76 69 60 SVR (%) 40 24 20 20 0 12-wk TPV+PR 24-wk TPV+PR 48-wk PR + 12-wk PR + 24-wk PR 12-wk TPV+PR 4-wk PR + 48-wk PR + 36-wk PR 12-wk TPV+PR + 32-wk PR REALIZE trial PROVE 3 trial McHutchison JG et al. NEJM 2010;362:1292-303. Zeuzem S et al. NEJM 2011;364:2417-28.

  6. Pooled T12/PR48 Pbo/PR48 REALIZE: SVR in G1 prior relapsers by baseline fibrosis stage Patients with SVR, % n/N 145/167 12/38 53/62 2/15 48/57 1/15 Stage No, minimal or portal Bridging fibrosis Cirrhosis fibrosis Pol S et al. Hepatology 2011;54(Suppl. S1): 374A-375A.

  7. Case 1 – AM – Question 2 If you retreat this patient with a triple combination, do you think that the virological response during a 4-week lead-in period with only Peg-IFN+RBV might offer useful information even in case of TPV based triple therapy? No Yes

  8. REALIZE (telaprevir): SVR by Week 4 on-treatment response according to prior response category <1 log10 HCV RNA reduction after 4-week Peg-IFN/RBV lead-in phase ≥1 log10 HCV RNA reduction after 4-week Peg-IFN/RBV lead-in phase P=0.001 SVR (%) Prior null responders15/28 Prior relapsers8/13 Prior partial responders10/18 Prior relapsers106/113 Prior partial responders16/27 Prior null responders6/41 n/N = Foster GR et al. J Hepatol 2011; 54 (Suppl.): S3.

  9. SVR by Week 4 on-treatment response in the LI T12/PR48 arm in prior relapsers Proportions of patients in each group 2% 8% 10% 14% 66% SVR (%) 0-0.5 0.5-1.0 1.0-1.5 1.5-2.0 >2.0 Reduction in HCV RNA at Week 4, log10 IU/mL n/N= 2/3 6/10 11/12 16/18 79/83 Zeuzem S et al. Hepatology 2011; 54 (Suppl. S1): 986A-987A.

  10. Case 1 – AM – Question 4 Would you retreat this patient with? • BOC based triple therapy • TPV based triple therapy • Any of the above combinations

  11. BOC or TPV in G1 prior relapsers without cirrhosis Stop treatment at Week 24 if RNA undetectable at Week 4 and 12 PR TPV + PR PR if RNA detectable at Week 4 or 12 Weeks 0 4 12 24 36 48 HCV RNA If >1000 IU/mL at Week 4 or 12: discontinue all drugs If detectable at Week 24 or 36:discontinue PR PR PRlead-in BOC + PR 36 Weeks 24 0 4 48 12 HCV RNA If ≥100 IU/mL: If detectable: Discontinue all drugs Boceprevir, Telaprevir EU SmPC

  12. Case 2 - GS 02/2009 • Female, 58 years, H 1.60 m, W 70 Kg, BMI 27.3 Kg/m2, Diabetes G1b, HCV RNA 2,000,000 IU/mL, Fibroscan 14.3 (1.9) kPa • Peg-IFNa-2b (100 μg/wk) +RBV (1.0 g/d) • HCV RNA 1,200,000 IU/mL at 12 wks – stop treatment 05/2009-12/2011 • Moderate ALT elevations, increased γ-globulin 12/2011 • HCV RNA 1,000,000 IU/mL, Fibroscan 17.5 (2.5) kPa

  13. Would you retreat this patient today? (BOC/TPV available) No Yes a. Peg-IFN + RBV b. Peg-IFN + RBV + BOC/TPV Case 2 – GS – Question 1

  14. REALIZE: SVR under TPV based therapy in G1 null responders P<0.001 Patients with SVR, % n/N 21/72 25/37 2/37 12-wk TPV+PR 4-wk PR + 48-wk PR + 36-wk PR 12-wk TPV+PR + 32-wk PR Zeuzem S et al. NEJM 2011;364:2417-28.

  15. REALIZE: SVR in G1 prior null responders by baseline fibrosis stage Pooled T12/PR48 Pbo/PR48 Patients with SVR, % n/N 24/59 1/18 16/38 0/9 7/50 1/10 Stage No, minimal or portal Bridging fibrosis Cirrhosis fibrosis Pol S et al. Hepatology 2011;54(Suppl. S1): 374A-375A.

  16. BOC in G1 null responders to PR PROVIDE study: prospective, one arm Patients Ν= 37 from SPRINT-2 (naive) N= 11 fromRESPOND-2 N= 42 HCV RNA >800.000 IU/ml N=31 G1a Duration of PR discontinuation: 5-112wks Patients, % n/N= 20/43 16/42 3/19 Vierling J et al. Hepatology 2011; 54 (Suppl. S1): 796A-797A.

  17. PROVIDE: SVR rates by baseline patient characteristics* Vierling J et al. Hepatology 2011; 54 (Suppl. S1): 796A-797A.

  18. Case 2 – GS – Question 2 If you retreat this patient with a triple combination, do you think that the virological response during a 4-week lead-in period with only Peg-IFN+RBV might offer useful information even in case of TPV based triple therapy? No Yes

  19. SVR rates ofnull responderstoPR under BOC+PR in relation to virological response during the lead-in period Proportions of patients in each group 76% 24% 38% 38% 21% 3% SVR (%) <1.0 ≥1.0 <0.5 0.5-<1.0 1.0-<1.5 1.5-2.0 Reduction in HCV RNA at Week 4, log10 IU/mL n/N= 11/32 5/10 6/16 5/16 5/9 0/1 Vierling J et al. Hepatology 2011; 54 (Suppl. S1): 796A-797A.

  20. REALIZE (telaprevir): SVR by Week 4 on-treatment response according to prior response category P=0.001 <1 log10 HCV RNA reduction after 4-week Peg-IFN/RBV lead-in phase ≥1 log10 HCV RNA reduction after 4-week Peg-IFN/RBV lead-in phase SVR (%) Prior null responders15/28 Prior relapsers8/13 Prior partial responders10/18 Prior relapsers106/113 Prior partial responders16/27 Prior null responders6/41 n/N = Foster GR et al. J Hepatol 2011; 54 (Suppl.): S3.

  21. SVR by Week 4 on-treatment response in the LI T12/PR48 arm in prior null responders Proportions of patients in each group 23% 36% 26% 7% 7% SVR (%) <0.5 0.5-1.0 1.0-1.5 1.5-2.0 >2.0 Reduction in HCV RNA at Week 4, log10 IU/mL n/N= 1/16 5/25 8/18 3/5 4/5 Zeuzem S et al. Hepatology 2011; 54 (Suppl. S1): 986A-987A.

  22. Case 2 – GS – Question 3 Would you retreat this patient with? BOC based triple therapy TPV based triple therapy Any of the above combinations

  23. BOC or TPV in G1 prior null responders PR TPV + PR Weeks 0 4 12 24 36 48 HCV RNA If >1000 IU/mL at Wk 4 or 12: discontinue all drugs If detectable at Wk 24 or 36:discontinue PR PRlead-in BOC + PR 24 Weeks 0 4 48 12 If ≥100 IU/mL If detectable HCV RNA Discontinue all drugs Boceprevir, Telaprevir EU SmPC

More Related